Clinical predictors of impaired pulmonary diffusing capacity in patients recovering from COVID-19: A secondary analysis of multicentre datasets
Canadian Journal of Respiratory Therapy · 14.07.2026 · 62
DOI: 10.29390/001c.164115 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Respiratory Therapy, online erschienen am 14.07.2026. Verfasst von Patchareeya Amput und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physical Therapy, School of Allied Health Sciences, University of Phayao, Phayao, Thailand University of Phayao. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Thailand Research Fund.
Abstract (Originalsprache)
Objective
This study aimed to identify clinical predictors of impaired pulmonary diffusing capacity in patients recovering from coronavirus disease 2019 (COVID-19) using a secondary analysis of multicentre datasets.
Methods
This secondary analysis included adults with laboratory-confirmed COVID-19 who underwent pulmonary function testing during the post-acute recovery phase. In total, 572 post-COVID-19 patients were included. Demographic characteristics and pulmonary function parameters were extracted from the datasets. Impaired pulmonary diffusing capacity for carbon monoxide (DLCO) was defined as a DLCO Z-score < -1.645 (below the lower limit of normal) according to Global Lung Function Initiative reference equations. Univariable logistic regression was used as an initial screening step, and variables with p < 0.10, together with clinically relevant variables, were considered for multivariable analysis.
Results
Of the 572 post-COVID-19 patients, 145 had impaired DLCO. Baseline characteristics differed significantly between patients with normal and impaired DLCO, particularly in age, sex, forced vital capacity (FVC), forced expiratory volume in one second (FEV1), and total lung capacity (TLC) ( p < 0.05). Age, sex, FVC, FEV1, and TLC were significantly associated with impaired DLCO in multivariable analysis. In multivariable logistic regression, age (adjusted OR 1.025; p = 0.002), female sex (adjusted OR 0.379; p < 0.001), and TLC (adjusted OR 0.603; p < 0.001) remained statistically associated with impaired DLCO. The model showed acceptable apparent discrimination in the development dataset (AUC 0.710).
Conclusions
Impaired pulmonary diffusing capacity was observed in approximately one-quarter of patients recovering from COVID-19. Older age, sex, and lower total lung capacity were independently associated with impaired DLCO in this secondary analysis. These findings should be interpreted as exploratory associations rather than causal or validated predictive effects.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Physical Therapy, School of Allied Health Sciences, University of Phayao, Phayao, Thailand University of Phayao.
- Department of Traditional Chinese Medicine, School of Public Health, University of Phayao, Phayao, Thailand University of Phayao.
Förderung
- Thailand Research Fund
Zitieren
APA
Amput, P., Tapanya, W., Sangkarit, N., Ladawan, S., & Wongphon, S. (2026). Clinical predictors of impaired pulmonary diffusing capacity in patients recovering from COVID-19: A secondary analysis of multicentre datasets. Canadian Journal of Respiratory Therapy, 62. https://doi.org/10.29390/001c.164115
Vancouver
Amput P, Tapanya W, Sangkarit N, Ladawan S, Wongphon S. Clinical predictors of impaired pulmonary diffusing capacity in patients recovering from COVID-19: A secondary analysis of multicentre datasets. Canadian Journal of Respiratory Therapy. 2026;62. doi:10.29390/001c.164115
BibTeX
@article{Amput2026,
author = {Amput, Patchareeya and Tapanya, Weerasak and Sangkarit, Noppharath and Ladawan, Suphannika and Wongphon, Sirima},
title = {Clinical predictors of impaired pulmonary diffusing capacity in patients recovering from COVID-19: A secondary analysis of multicentre datasets},
journal = {Canadian Journal of Respiratory Therapy},
year = {2026},
volume = {62},
doi = {10.29390/001c.164115}
}
EUVIMED